Agios
Agios is a Boston biotech company dedicated to the discovery and development of novel therapeutics in the emerging field of cancer metabolism.
Accelerate Brain Cancer Cure's investment is enabling Agios to explore whether the mutated IDH1 gene has an enzyme activity consistent with a cancer-causing gene, or oncogene. This work stems from a breakthrough discovery which showed that the mutated form of IDH1 produces a metabolite, which may contribute to the formation and malignant progression of gliomas. Agios is investigating opportunities to develop therapies for brain cancer and other cancers where IDH1 mutations are present using new drugs that can target the IDH1 metabolic pathway.